TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05655273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Participants randomized to the Prograf (control) arm will continue with their current twice daily dosing of Prograf.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envarsus
Description: Participants randomized to Envarsus arm will have their current daily dose of Prograf converted to once-daily Envarsus dose according to the following ratio: 0.7 x the current daily Prograf dose. Envarsus is available in 3 dose strengths- 0.75mg, 1.0mg, and 4.0mg. The actual dose of Envarsus will be rounded to an amount that can be administered using the above tablet strengths.
Study: NCT06499298

Intervention type: DRUG
Intervention: Nivolumab
Description: As per product label, as prescribed by treating physician
Study: NCT05916313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764532
Description: BI 764532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764532
Description: BI 764532
Study: NCT05996432

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Participants will undergo Magnetic Resonance Imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Participants will undergo Magnetic Resonance Imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Participants will undergo Positron Emission Tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Participants will undergo Positron Emission Tomography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluoromisonidazole
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluoromisonidazole
Description: Given by IV
Study: NCT06075316

Intervention type: OTHER
Group type: OTHER
Intervention: Symptom monitoring
Description: Alerts will be sent to providers via email and/or the electronic medical record at pre-specified response thresholds. Providers will be instructed to respond to and document the management of alerts per their clinical routine.
Study: NCT05249647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument based Fascial abrasion technique
Description: Participants were in a comfortable position during treatment. Emollient (anti-allergic) was applied to prevent skin irritation prior to Fascial Abrasion application. Each session included 1 minute of sweeping (longitudinal strokes performed parallel to the muscle fibers similar to compression with oscillations) directly over the Myofascial trigger points, 2 minutes of fanning (one end of the instrument was held in place \& the other end moved through a semicircular pattern similar to petrissage) and concluded with 1 min of sweeping. Fascial Abrasion tool was washed in alcohol-based sanitizer before and after every treatment session and all norms of COVID-19 precautions were maintained. Myofascial trigger points were marked with a 1×1 cm piece of tape/under wrap to confirm consistency of subsequent treatments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial release technique
Description: All participants will get Conventional therapy i.e heating pad for 10 minutes. For the application of technique, the patient position will be supine lying with head fully supported on therapist hands and therapist places 3 middle fingers just inferior to the nucle line, lifts the finger tips towards the ceiling while resting the head on the table and then therapist applied a gentle upward pull. This procedure done for 2-3 minutes, 5-7 repetitions, 3 sessions per week on alternate days given for 6 weeks.
Study: NCT05212727

Intervention type: DEVICE
Intervention: Eye-tracking
Description: Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
Study: NCT04942366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: HIIT using treadmill four sets of 4 minute interval session (at 90%-95% of the individual HR max calculated by using the karvonen method) and each set will be followed by three minute of moderate intensity exercise (at 70% of individual HR max).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: Strength training will be performed thrice a week, each session will consist of eight dynamic drills.
Study: NCT06049589

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coconut Oil
Description: Coconut oil rinsing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: Chlorhexidine rinsing

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water mouthwash
Description: Control with water rinsing
Study: NCT04805671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG20
Description: Single dose of ADG20

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Single dose of normal saline
Study: NCT05569798

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole body point of care ultrasound scan
Description: The INSIGHT Scan is a whole-body PoCUS scan which comprises imaging the following windows:~1. subcostal~2. inferior vena cava cardiac view~3. left hemidiaphragm~4. bladder~5. right hemidiaphragm~6. six major central veins (left/right internal jugular/ subclavian/ femoral veins)~The scan should take no more than 10 minutes to perform. Simple yes/no questions are asked for each window to identify any significant abnormalities. For example, is the left ventricle bigger than the right ventricle; is there a pleural effusion; is the bladder distended etc.~The scan is reported in the intensive care online medical notes and reviewed by the clinical team as soon as possible.
Study: NCT05043116

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol D3
Description: 2000 IU of Vitamin D provided as oral suspension for one year

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo suspension
Description: Oral suspension with no active substance tasting like the active supplement.
Study: NCT04915560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected T-shirt
Description: Ware of a connected T-shirt
Study: NCT05619731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric oncology tele-consultation and pharmaceutical tele-expertise
Description: tele consultation
Study: NCT05460546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jincaopian Tablets high dose
Description: Jincaopian Tablets 0.2g tid p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jincaopian Tablets low dose
Description: Jincaopian Tablets 0.1g tid p.o.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tid p.o.
Study: NCT05628246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Telemedicine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-person
Description: In-person
Study: NCT05550350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexycu
Description: 103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Vehicle
Description: Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg
Study: NCT04754893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Healthdot application
Description: Healthdot device is applied on subject's chest after surgery
Study: NCT04528134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended Contact RMGI (Resin-modified Glass Ionomer) Varnish
Description: This is a light-cured, durable coating that forms an immediate layer of protection that releases fluoride, calcium and phosphate and can be recharged with fluoride by using fluoride-containing products over the 6-month life of the product.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended Contact RMGI (Resin-modified Glass Ionomer) Varnish
Description: This is a light-cured, durable coating that forms an immediate layer of protection that releases fluoride, calcium and phosphate and can be recharged with fluoride by using fluoride-containing products over the 6-month life of the product.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5% Sodium Fluoride Varnish
Description: This is a 5% Sodium Fluoride varnish that hardens on the teeth upon contact with saliva.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5% Sodium Fluoride Varnish
Description: This is a 5% Sodium Fluoride varnish that hardens on the teeth upon contact with saliva.
Study: NCT05500677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine topical
Description: Lidocaine spray, which is a quick and easy-to-use topical local anesthetic, will be applied as a puff to the painful area.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine topical
Description: Lidocaine spray, which is a quick and easy-to-use topical local anesthetic, will be applied as a puff to the painful area.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine topical
Description: Lidocaine spray, which is a quick and easy-to-use topical local anesthetic, will be applied as a puff to the painful area.
Study: NCT05483413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive relaxation exercises
Description: Progressive relaxation exercises are a cognitive behavioral technique that provides relaxation in the muscles that individuals can do alone.
Study: NCT05909826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 70 mg/m2 IV days 1, 8 and 15, every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg PO days 1 to 21, every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40mg PO or IV days 1, 8, 15, and 22, every 4 weeks
Study: NCT06451640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 210mg of TQC2731 injection
Description: TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 420mg of TQC2731 injection
Description: TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody.
Study: NCT05781191

Intervention type: BIOLOGICAL
Intervention: COMIRNATY
Description: Booster (3rd) dose of COMIRNATY Seasonal dose of influenza vaccination based on patient's individual risk factors
Study: NCT06479031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Occupational Therapy intervention, once a day, for 5 days, for 40 minutes each session.
Study: NCT04921475

Intervention type: DEVICE
Intervention: Regional oxygen saturation monitoring
Description: Regional oxygen saturation of kidney is monitored using near infrared spectroscopy
Study: NCT06214741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: survodutide
Description: once weekly subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: survodutide
Description: once weekly subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 456906
Description: Once weekly subcutaneous injection
Study: NCT05282628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Better Brains and Behavior program (B4 Preterm)
Description: The program couples online learning modules with video conferencing sessions with a trained therapist to review skills and practice implementing the skills with live coaching. Online modules include didactic content, video clips of parents modeling the skills, and exercises. Parents will complete intervention modules sequentially in conjunction with scheduled 1:1 videoconference sessions with a trained therapist. Videoconference sessions with the therapist will be scheduled weekly, once parents have completed their modules. During these sessions, the therapist will review the online materials and provide active coaching to the parent on how to use the skills with their child (e.g., labeled praise, reflective responses). Each session follows a manualized therapy protocol to optimize content fidelity. Parents will be instructed to practice the parenting skills for 5 minutes each day to promote mastery in the home environment.
Study: NCT05222555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: tafasitamab will be administered intravenously at protocol defined timepoints

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: lenalidomide will be administered orally at protocol defined timepoints
Study: NCT05572645

Intervention type: DRUG
Intervention: Pyrotinib Plus Trastuzumab
Description: treatment based on Pyrotinib(320-400 mg, po, qd) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)

Intervention type: DRUG
Intervention: Pertuzumab Plus Trastuzumab
Description: treatment based on Pertuzumab(840mg q3w, and then 420 mg q3w) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
Study: NCT05465447

Intervention type: DEVICE
Intervention: subjective refraction
Description: Short-term postoperative (1-3 months) and long-term postoperative (3-5 years) subjective optometry results were measured by subjective refraction.
Study: NCT05294120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reflectance ConfocaL Microscopy And Optical Coherence Tomography Guided
Description: Patients will undergo RCM/OCT with an imaging specialist in the Dermatology Service.~This is not expected to take longer than 30 minutes. Prior to imaging, a digital photograph will be taken of the biopsy proven BCC.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: After the completion of skin imaging, patients will undergo simulation and tumor radiotherapy. An equivalent total dose in 2 Gy fractions (EQD2) of 45-46 Gy will be delivered for treatment.
Study: NCT04483466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate is vibrant yellow-orange colored powder with physical properties of near insolubility in water formulated into methotrexate tablets containing an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, and yellow. The chemical name is N-\[4-\[\[(2,4-diamino-6pteridinyl)methyl\]methyl amino\]benzoyl\]-L-glutamic acid. Methotrexate is an anti-metabolite that is a folate antagonist that inhibits lymphocyte proliferation and functions as an immunosuppressant in arthritis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06138613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tradipitant
Description: Oral Capsule
Study: NCT04652557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fampridine SR
Description: Fampridine SR is an inhibitor of voltage gated potassium channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: no active component
Study: NCT06005363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: dexmedetomidine infusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anesthesia depth monitoring
Description: intraoperative anesthesia depth monitoring to keep BIS 40-60

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anesthesia depth monitoring
Description: intraoperative anesthesia depth monitoring to keep BIS 40-60
Study: NCT04462783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptoms entered into the CovidX application
Description: Participants are asked to enter symptoms into the CovidX application at least daily for 30 days. Additionally, they will enter demographic information and some survey information will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptoms entered into the CovidX application
Description: Participants are asked to enter symptoms into the CovidX application at least daily for 30 days. Additionally, they will enter demographic information and some survey information will be collected.
Study: NCT06381180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol
Description: Plant cannabis that will be vaporized

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol
Description: Plant cannabis that will be vaporized

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Plant cannabidiol that will be vaporized

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Plant cannabidiol that will be vaporized

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Plant will be vaporized.
Study: NCT05877911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Sulfate
Description: Sodium thiosulfate has previously been reported to reduce the incidence of acute kidney injury after HIPEC with cisplatin, but this finding has not been confirmed in a high-level study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydration
Description: On the day of surgery, the day of HIPEC, and 24 hours after HIPEC, daily intravenous rehydration should be performed using natrium chloride, glucose chloride or potassium chloride. The amount of fluid to be replenished should not be less than 3000 milliliters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydration
Description: On the day of surgery, the day of HIPEC, and 24 hours after HIPEC, daily intravenous rehydration should be performed using natrium chloride, glucose chloride or potassium chloride. The amount of fluid to be replenished should not be less than 3000 milliliters.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Infuse cisplatin (75mg/m\^2) at 43℃ through the two drainage tubes placed in the upper abdomen, using the two drainage tubes placed in the lower abdomen as the effluent tubes, with an infusion time of 60-90 minutes and an infusion rate of 500-600 mL/min. The first HIPEC should be performed within 24-48 hours after cytoreductive surgery. The second HIPEC should be performed 24 hours after the completion of the first HIPEC. Intravenous sedatives such as dexmedetomidine or propofol at 2-6 ml/h should be administered during HIPEC treatment with continuous intravenous infusion by a pump，or intramuscular injection of 50 mg of pethidine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Infuse cisplatin (75mg/m\^2) at 43℃ through the two drainage tubes placed in the upper abdomen, using the two drainage tubes placed in the lower abdomen as the effluent tubes, with an infusion time of 60-90 minutes and an infusion rate of 500-600 mL/min. The first HIPEC should be performed within 24-48 hours after cytoreductive surgery. The second HIPEC should be performed 24 hours after the completion of the first HIPEC. Intravenous sedatives such as dexmedetomidine or propofol at 2-6 ml/h should be administered during HIPEC treatment with continuous intravenous infusion by a pump，or intramuscular injection of 50 mg of pethidine.
Study: NCT06080009

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: exome sequencing (retrospective) and exome and methylome sequencing (prospective)
Description: Three to nine sections will be used as the source of DNA for each tumor. The pathologist will identify and separate tumor tissue from normal tissue, and the two DNAs will be sequenced separately. Variants obtained from tumor and normal tissue will be compared, with different outcomes. Expected in this way are 1) somatic/tumor-specific variants (which are absent in normal tissue), 2) variants lost during tumor evolution due to segmental chromosomal deletion or other mechanisms that cause loss of heterozygosity. Using these two classes of variants, a clustering analysis will be performed at the end of the sequencing project to better define the phenotype and molecular signature of the tumors. In the prospective part of the project, the new tumors will be frozen fresh. This resource will allow methyloma analysis to be performed.
Study: NCT05504096

Intervention type: DEVICE
Group type: OTHER
Intervention: Actxa BGM Tracker (GLO2)
Description: Wrist-worn wearable

Intervention type: DEVICE
Group type: OTHER
Intervention: SVT In-Ear Prototype (IEP)
Description: In-Ear wearable
Study: NCT06116578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: cf Arm A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab and Olaparib
Description: cf Arm B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab adjuvant
Description: After surgery (adjuvant phase), all patients (Arm A and B) will receive pembrolizumab 200 mg two intravenous (IV) infusions q3w for one-year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab adjuvant
Description: After surgery (adjuvant phase), all patients (Arm A and B) will receive pembrolizumab 200 mg two intravenous (IV) infusions q3w for one-year
Study: NCT05863650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital based simulation
Description: Algorithms will be created for various musculoskeletal diseases and these algorithms will be controlled by taking the opinions of physiotherapists and physicians who are experts in their fields. After the algorithms are created, a website with patient scenarios containing these algorithms will be established with the support of a software company. In addition to the website, a database will be created and the applications made on the site will be recorded. In this way, the data of users using the website will be collected.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face to face education
Description: In the face-to-face education group, two case analyzes will be applied by the students together with the educators themselves in the classroom environment, with the educational content prepared in parallel with the patient scenarios in the simulation-based education group.
Study: NCT05662020

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)
Description: 9-19 years group (3 doses) and 20-26 years group (3 doses) will be vaccinated at months 0, 2, 6. 9-14 years group (2 doses) will be vaccinated at months 0, 6.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GARDASIL® 9
Description: 20-26 years possitive control group will be vaccinated at months 0, 2 and 6